A subset of patients with metastatic prostate cancer who showed evidence of pretreatment of active T-cell responses in tumors experienced prolonged survival data as a result of treatment with ipilimumab, according to a study published in Science Translational Medicine.1
The phase II trial found that a group of patients with metastatic castration-resistant prostate cancer, which typically has a limited response to immunotherapy, could benefit from immune checkpoint inhibitors and provide future biomarkers to identify this subgroup.
“Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, MD, PhD, in a press release.2 “We found specific markers among a subset of patients with the greatest benefit, such as T-cell density and interferon-γ…